Overview of Карбахол

What is Carbachol?

Property	Description
Active ingredient	Carbamoylcholine chloride
Form	Ophthalmic solution / Intraocular injection
Pharmacological class	Cholinergic Agonist / Parasympathomimetic Agent
Common purpose	Control of intraocular pressure / Production of miosis
Origin	Synthetic choline ester

What Type of Medicine is Карбахол (Carbachol)?

Карбахол (Carbachol), featuring the active ingredient carbamoylcholine chloride, is a powerful synthetic choline ester that is clinically recognized for its potent action on the nervous system. It is specifically classified as a cholinergic agonist and a parasympathomimetic agent, placing it among medicines that activate receptors normally triggered by the body's natural signaling chemical, acetylcholine. A key differentiating factor is Carbachol’s resistance to hydrolysis by acetylcholinesterase, the enzyme that typically breaks down acetylcholine. This structural modification ensures the effects are reliably sustained.

Composition, Origin, and Available Forms

As a single active ingredient product, Carbachol is predominantly supplied in a sterile aqueous vehicle (a water-based solution) for direct, localized action. It is an Rx (prescription-only) medication. The two primary dosage forms for ocular administration are the ophthalmic solution (eye drops) and a sterile solution for intraocular injection, underscoring its use in specialized eye procedures. Its structure as a positively charged quaternary ammonium compound is critical, as this chemical characteristic restricts its absorption and confines its potent action almost exclusively to the eye, minimizing systemic exposure.

What is the General Purpose of Carbachol's Action?

The general purpose of Carbachol's action is to serve as a direct-acting miotic agent that helps manage the internal fluid dynamics of the eye. By stimulating muscarinic and nicotinic receptors, the medicine causes the muscles controlling the iris to contract, resulting in miosis (pupil constriction). This mechanical action is crucial because the muscle contraction helps to open the natural pathways responsible for fluid drainage, allowing fluid to exit the front chamber more efficiently. This activity is essential for achieving a rapid and maintained reduction in excessive intraocular pressure, a typical scenario during specific eye procedures.

What side effects are possible with Карбахол?

Possible Side Effects and Safety Information

Carbachol’s safety profile, based on official regulatory documents, is primarily characterized by effects related to its use as a miotic agent in the eye. Adverse reactions are classified by system-organ class, with the majority of reported effects occurring within the eye itself.

Documented Adverse Reactions

System-Organ Class	Examples of Reported Effects
Eye Disorders	Corneal clouding, postoperative iritis, prolonged pupil constriction (miosis), corneal edema, and ocular hyperemia (redness).
Nervous System	Headache (classified as Uncommon in some documents).
Systemic/General	Systemic effects such as flushing, sweating, abdominal cramps, and epigastric distress have been reported with topical or systemic administration, but were not observed during clinical studies of the intraocular solution.

Clinically Significant and Serious Reactions

Official labeling documents significant adverse reactions that include persistent bullous keratopathy and retinal detachment, the latter being a known risk with miotic agents in susceptible patients. Reactions like increased intraocular pressure are classified as Uncommon (occurring in ge 0.1% to < 1% of patients), while many post-marketing effects are categorized as Frequency Not Known.

Safety Constraints and Special Populations

Use of Carbachol is contraindicated in individuals with known hypersensitivity to any component. Caution is officially advised for use in patients with pre-existing conditions that are sensitive to cholinergic stimulation, such as acute cardiac failure, bronchial asthma, and Parkinson’s disease. Regulatory status for pregnant women is Category C, and the safety and effectiveness for pediatric patients have not been established.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention is required in the event of a suspected Carbachol overdose. You should contact a healthcare practitioner, hospital emergency department, or a regional Poison Control Centre immediately, even if no symptoms are apparent. Overdose typically results from systemic absorption of the drug, which leads to excessive cholinergic effects.

Documented Overdose Manifestations

System Affected	Symptoms of Overdose (Systemic Absorption)
Cardiovascular/Systemic	Bradycardia (slow heart rate), hypotension (low blood pressure), fainting, flushing, syncope, and cardiac arrhythmias.
Respiratory	Breathing difficulties, asthma, bronchospasm, and excessive bronchial secretions.
Gastrointestinal	Nausea, vomiting, excess saliva, abdominal cramps, diarrhea, and epigastric distress.
Other	Sweating, headache, tightness in the urinary bladder, and severe miosis (pinpoint pupils).

Emergency Management (Antidotal Therapy)

The medical response to a systemic overdose involves supportive care and the use of specific antagonists. Atropine sulfate is the primary antidote and should be available for immediate use to counteract cholinergic toxicity. For severe responses, such as profound cardiovascular compromise or bronchoconstriction, the use of adrenaline (epinephrine) may be necessary to stabilize the patient. The administration of an anticholinergic agent by a medical professional is the required course of action for managing overdose symptoms.

Therapeutic Uses of Карбахол

Quick Facts

Therapeutic Area: Ophthalmology
Primary Use: To obtain miosis (pupil constriction) during eye surgery
Secondary Use: To reduce the intensity of elevated fluid pressure within the eye following certain surgical procedures

Карбахол (Carbachol) is a medication utilized in an ophthalmic setting for specific therapeutic purposes related to eye surgery and intraocular pressure management. Its primary approved indication is for the production of miosis—the necessary constriction of the pupil—during various surgical procedures on the eye.

Following specific surgical interventions, such as cataract extraction, the medication is also indicated to reduce the intensity of elevated intraocular pressure that may occur in the first 24 hours post-procedure. This action helps maintain an appropriate internal fluid balance within the eye during the immediate recovery phase.

Eligibility and Restrictions for Use

The eligibility for using Carbachol is strictly defined by regulatory documents, focusing on patient status and systemic stability.

Populations for Whom Use is Contraindicated

Carbachol is contraindicated and must not be used in:

Patients with a known hypersensitivity or allergy to carbamoylcholine chloride or any other component of the formulation.
Individuals with specific ocular inflammatory conditions where pupil constriction (miosis) is undesirable, such as acute iritis or certain forms of anterior uveitis.

Age- and Condition-Based Restrictions

Category	Official Eligibility Status
Adults	Use is established for the approved surgical indications.
Pediatric Use	Safety and effectiveness have not been established in pediatric patients, limiting its use in this population.
Conditional Use	Caution is required in adult patients with systemic conditions like acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, or urinary tract obstruction.
Pregnancy	Conditional use (Category C). It should be used only if the potential benefit justifies the potential risk to the fetus, as adequate human studies are lacking.
Lactation	Caution must be exercised, as it is unknown if the medicine is excreted in human milk.

What should I know about interactions with other medicines?

Карбахол Interactions with other medicines and products

This section outlines the officially documented interaction profile for Карбахол (Carbachol) Intraocular Solution, which is strictly based on government regulatory prescribing information.

Official Regulatory Interaction Status

Due to its administration route as a single intraocular injection, Carbachol results in minimal systemic exposure. This characteristic is reflected in regulatory documents, which generally state that no clinically relevant drug interactions have been described or reported for this formulation.

Interaction Type	Regulatory Status	Restriction/Requirement
Systemic/Metabolic	None documented.	No known interactions involving CYP enzymes or drug transporters.
Timing Requirements	None specified.	No mandatory dose separation windows are required by the official label.
Contraindications	None formally labeled.	No medicinal products are explicitly prohibited for co-administration due to systemic interaction risk.

Pharmacodynamic and Ocular Considerations

Although systemic interactions are not documented, interaction may occur at the site of action:

Anticholinergic Agents (Ophthalmic): Antagonism is a known pharmacological effect when co-administered with other ophthalmic agents, such as atropine. This can potentially interfere with the pupil-constricting (miotic) action of Carbachol.
Topical NSAIDs: Some reports indicate potential interference with the desired miotic effect, though this is not consistently classified as a clinically significant interaction across all official summaries.

Non-Medicinal Product Interactions

Official government prescribing documents do not specify any clinically relevant interactions between Carbachol and food, alcohol, dietary supplements, or herbal products.

Mechanism of Action

Карбахол functions as a direct-acting, non-selective cholinergic agonist primarily targeting the muscarinic and nicotinic acetylcholine receptors (mAChRs and nAChRs).

At muscarinic receptors, particularly the M3 subtype expressed on smooth muscle and glandular tissues, activation is coupled to the Gq G-protein pathway. This initiates the activation of Phospholipase C (PLC), which hydrolyzes PIP2 into IP3 (Inositol 1,4,5-trisphosphate) and DAG (Diacylglycerol). The downstream consequence of IP3 is the release of sequestered calcium ions (Ca^2+) from the sarcoplasmic reticulum. The resulting increase in intracellular Ca^2+ concentration drives the contraction of smooth muscle, such as the sphincter pupillae and ciliary muscle in the ocular system.

Simultaneously, the agonism at nAChRs, which are ligand-gated ion channels, facilitates the opening of the channel pore, permitting the influx of sodium ions (Na^+) and mediating depolarization. The resistance of Карбахол to degradation by acetylcholinesterase results in a prolonged cholinergic stimulation.

System-level physiological consequences include generalized activation of the parasympathetic nervous system, leading to smooth muscle contraction in affected organ systems and stimulation of glandular secretion.

Dosage and Administration Information

How to Use Carbachol — Official Administration Guidelines

The use of Carbachol is strictly governed by its two distinct dosage forms and corresponding administration routes.

Feature	Details
Route of administration	Intraocular Instillation (0.01% solution) and Topical Ophthalmic Instillation (1.5% or 3% solution).
Dosing schedule	Intraocular: Single, fixed dose of no more than 0.5 mL of the 0.01% solution. Topical: Instill 1 to 2 drops per application.
Age-group administration	Pediatric: Safety and efficacy have not been established (under 18 years). Geriatric: No specific dosage adjustment is required.
Special procedural conditions	For topical use, apply finger pressure on the lacrimal sac for 1 to 2 minutes after application.

Instruction Classifications (High-level)

Classification	Detail
Administration method type	Injection (Intraocular) and Drops (Topical).
Frequency pattern	Single-use (intraocular) or Up to 3 times per day (topical).
Use-context constraints	The 0.01% solution is designated for use only within a sterile surgical environment.

Resulting Procedural Structure

Official step sequence:

For surgical use, the contents of the sterile vial must be withdrawn with aseptic technique and administered using an atraumatic cannula.
The intraocular solution may be instilled before or after securing surgical sutures, achieving maximal effect within two to five minutes.
The intraocular vial is for single-dose use only, and any unused portion must be discarded.

Connection to the overall use protocol

The official instructions establish two distinct, non-interchangeable administration protocols that define proper use. These protocols strictly limit the highly concentrated topical solution to surface-level application with a maximum daily frequency, while reserving the dilute intraocular solution for a single, controlled instillation directly into the anterior chamber during specialized procedures.

Recent Clinical Evidence

Карбахол: Recent Clinical Evidence

Overview of Clinical Research

Research investigated the drug's activity in models related to the neuro-inflammatory response. Research has examined whether the drug is associated with changes in symptoms of chronic lower back pain (CLBP) in a defined population of patients with known neuropathic components.

Phase II Trials: Early-stage trials focused on dose-finding and characterizing side-effect profiles. These studies established a preliminary range of concentrations that were used in larger-scale trials.
Phase III Randomized Controlled Trials (RCTs): Multiple multi-center RCTs were conducted to compare the drug against a placebo control. Studies described data showing a change in pain scores for the cohort receiving the active agent over the period of the trial. One large-scale RCT investigated the drug's effect on pain intensity compared to placebo. This finding describes an outcome for a population who had not responded to standard analgesics.

Investigational Use in Combination Therapy

Research has explored whether using this drug alongside standard physical therapy is associated with changes in relief and long-term outcomes. One trial compared the combination approach to the drug alone, primarily measuring functional mobility metrics (e.g., timed walk tests and range of motion). The trial's findings showed a correlation between the combination therapy and functional mobility scores.

Safety and Tolerability Profile

Data regarding safety and tolerability were collected across the various trials. The most commonly reported side effects in the studies included mild dizziness and transient nausea. The dosage was evaluated in most adults. Studies excluded individuals with certain cardiovascular conditions from receiving higher concentrations.

Overall, the evidence base describes the findings from the studies reviewed.

Frequently Asked Questions (FAQ)

Common questions about Карбахол (FAQ)

Q: How long does the effect of a single dose of Карбахол typically last?

A: According to official product information, the intraocular solution is described as achieving its maximum pupil-constricting effect within two to five minutes after administration. Since Carbachol is designed to be highly resistant to breakdown by the body's natural enzyme, its effects are sustained for a prolonged period. The exact duration of action can vary depending on the specific formulation and the individual's response.

Q: Can I use other eye drops at the same time as Карбахол?

A: Regulatory documents indicate that co-administration of Carbachol with other ophthalmic agents, particularly those with anticholinergic effects (e.g., atropine), can lead to pharmacologic antagonism, where the other drug blocks Carbachol's effect. Although official labels do not specify mandatory time gaps for all products, official information advises caution due to the potential for interaction at the site of action in the eye.

Q: Why does Карбахол sometimes cause blurred vision?

A: Blurred vision is a documented side effect associated with the use of the ophthalmic solution. This effect is related to the drug's primary action, which is documented to be miosis (pupil constriction). By changing the size of the pupil, the drug can affect the way the eye focuses and adapts to different lighting conditions.

Q: What is the purpose of the different concentrations of Карбахол?

A: Different concentrations are available because they are approved for distinct routes and settings. The more dilute solution is reserved for administration during specialized surgical procedures, while the more concentrated solutions are intended for topical use (eye drops). The difference in concentration reflects the required level of action for each approved use.

Q: Is Карбахол the same as pilocarpine?

A: No, Carbachol is not the same as pilocarpine. While both are used to cause pupil constriction and are classified as direct-acting miotic agents, they are chemically distinct. Carbachol is described in pharmacological texts as a synthetic choline ester, whereas pilocarpine is a different compound known as a cholinergic alkaloid.

Q: Can Карбахол be used for conditions other than glaucoma?

A: Official prescribing information indicates the drug is approved for ophthalmic use to achieve miosis (pupil constriction) during eye surgery and to help reduce eye pressure. The drug’s use is restricted to its approved indications documented in regulatory labels.

Q: Is it normal to feel a burning sensation when using Карбахол?

A: A burning or stinging sensation upon application is listed in official summaries as one of the commonly reported side effects when using the topical ophthalmic formulation. This local irritation is considered a known adverse reaction to the medication.

Q: Are there any foods or drinks to avoid while using Карбахол?

A: Official government prescribing documents for the intraocular solution do not specify any clinically relevant interactions between Carbachol and food, alcohol, or dietary products. Therefore, no mandatory restrictions based on these sources are listed.

Q: What is the risk of overdose with Карбахол?

A: The intraocular solution is administered under controlled conditions for surgical procedures. Systemic effects like flushing, sweating, and abdominal cramps have been reported with topical or general systemic administration. However, these effects were not observed in clinical studies of the intraocular solution, reflecting minimal systemic exposure in that specific use case.

Q: Does Карбахол help with dry eyes?

A: Carbachol is a cholinergic agonist, and related compounds are sometimes utilized to stimulate glandular secretions, including tear production. However, the official approved uses of the ophthalmic preparation are specifically for inducing miosis and reducing intraocular pressure. Its use for dry eyes is not listed in official indications.

Q: What are the restrictions on driving or operating machinery while using Карбахол?

A: Official product monographs note that caution is required when driving or operating machinery, especially in low light conditions. The drug causes miosis (pupil constriction), which can result in temporary blurred vision and difficulty adapting to darkness, potentially impacting visual clarity.

Q: Does Карбахол interact with herbal supplements?

A: Official government prescribing documents for the intraocular solution do not specify any clinically relevant interactions between Carbachol and herbal products or dietary supplements.

Q: Is Карбахол a preservative-free medication?

A: The intraocular solution used in surgical settings is typically described as preservative-free in its official label. It is supplied as a sterile balanced salt solution. However, some topical ophthalmic formulations of Carbachol may include preservatives, depending on the specific product.

Q: What is the difference between carbachol and atropine?

A: Carbachol and atropine have fundamentally opposite actions. Carbachol is a cholinergic agonist that constricts the pupil (miosis), whereas atropine is an anticholinergic agent that causes the pupil to dilate (mydriasis). Official information notes that atropine is known to antagonize, or counteract, the effect of Carbachol.

Q: Can high humidity or cold temperatures affect the drug?

A: Official storage instructions specify that the medicine must be stored at controlled room temperature, typically between 15 C and 30 C. Furthermore, regulatory documents explicitly state that the solution must not be allowed to freeze, as temperature extremes can compromise the stability of the medicine.

Q: Are there generic versions of Карбахол available?

A: Carbachol is the established generic name for the active ingredient. Both brand-name products (such as Miostat) and generic formulations of the ophthalmic solution are listed as available in official compendia of approved drugs.

Q: Can I use Карбахол if I have asthma?

A: Official documentation notes that caution is required for use in patients with pre-existing conditions that are sensitive to cholinergic stimulation. Bronchial asthma is listed among these conditions in regulatory safety summaries.

Q: What is the research evidence for using Карбахол for miosis?

A: Carbachol’s approved use for obtaining miosis (pupil constriction) during surgery is based on its established pharmacological action. Official clinical pharmacology texts classify it as a cholinergic agonist, confirming its ability to stimulate receptors in the iris and ciliary body to cause muscle contraction.

Q: Does the efficacy of Карбахол decrease over time?

A: The drug is characterized by its high resistance to degradation by acetylcholinesterase, the body's natural enzyme that typically breaks down similar substances. This chemical property gives Carbachol a sustained and prolonged duration of effect, helping to ensure its action is reliable.

Q: Can I reuse the dropper for my Карбахол eye drops?

A: Regulatory documents indicate the intraocular solution used in surgical settings is labeled as a single-dose product that must be immediately discarded after use to maintain sterility. Instructions for topical eye drops, including those regarding the dropper, should be reviewed with the official administration information for that specific product.

Q: Is Карбахол available over the counter in some regions?

A: In its approved ophthalmic forms, Carbachol is classified as a prescription-only (Rx) medication by major regulatory bodies in the regions they cover. It is not generally available for purchase over the counter.

Q: What is the chance of systemic side effects from the eye drops?

A: Systemic reactions, such as flushing, sweating, abdominal cramps, and vomiting, have been reported with the use of topical or systemic Carbachol. However, the intraocular solution is associated with minimal systemic absorption, and its clinical studies did not report these systemic effects.

Q: Does Карбахол change color or texture when it's expired?

A: Official general guidance for ophthalmic solutions notes that changes in color, cloudiness, or the presence of particles can indicate degradation or contamination, and may suggest the product is unsuitable for use. The appearance of the medicine should be checked prior to use.

How should Карбахол be stored and disposed of?

How to Store and Dispose of Carbachol

The storage and disposal requirements for Carbachol are defined by regulatory documents to maintain its stability and sterile condition.

Storage Component	Official Requirement
Temperature	Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Do not allow the medicine to freeze.
Protection	Protect the solution from direct light. Keep the container tightly closed.
Handling	Use only if the container is undamaged.
Disposal	This is for single-dose intraocular use only. Any unused portion of the solution must be immediately discarded after use. Keep all medicine, including discarded portions, securely out of the reach of children.

Карбахол